{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:28Z","timestamp":1793191768954,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of complications of their disease. Emicizumab is the first bispecific monoclonal antibody prophylactic therapy for PwHA, and its efficacy and safety have been previously demonstrated; however, there is a need to build an evidence base on the management of PwHA on emicizumab undergoing surgery. Data from the HAVEN 1-4 phase 3 clinical trials were pooled to provide a summary of all minor and major surgeries in PwHA with or without factor VIII (FVIII) inhibitors who were receiving emicizumab prophylaxis. Overall, 233 surgeries were carried out during the HAVEN 1-4 trials: 215 minor surgeries (including minor dental and joint procedures, central venous access device placement or removal, and\u00a0endoscopies) in 115 PwHA (64 with FVIII inhibitors) and 18 major surgeries (including arthroplasty and synovectomy) in 18 PwHA (10 with FVIII inhibitors). Perioperative hemostatic support was at the discretion of the treating physician. Overall, the median (interquartile range [IQR]) age was 33.5 (13.0-49.0) years and the median (IQR) emicizumab exposure time before surgery was 278.0 (177.0-431.0) days. Among the 215 minor surgeries, 141 (65.6%) were managed without additional prophylactic factor concentrate, and of those,\u00a0121 (85.8%) were not associated with a postoperative bleed. The majority (15 of 18\u00a0[83.3%]) of major surgeries were managed with additional prophylactic factor concentrate. Twelve (80.0%) of these 15 surgeries were associated with no intraoperative or\u00a0postoperative bleeds. The data demonstrate that minor and major surgeries can be performed safely in PwHA receiving emicizumab prophylaxis. These trials are registered at\u00a0www.clinicaltrials.gov as #NCT02622321, #NCT02795767, #NCT02847637, and #NCT03020160.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007458","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T20:04:03Z","timestamp":1659989043000},"page":"6140-6150","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-5240","authenticated-orcid":false,"given":"Rebecca","family":"Kruse-Jarres","sequence":"first","affiliation":[{"name":"1Washington Center for Bleeding Disorders, Seattle, WA"},{"name":"2Division of Hematology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"3Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia, Milan, Italy"},{"name":"4Thrombosis Center and Universit\u00e0 degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"5University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"6Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Chebon","sequence":"additional","affiliation":[{"name":"7F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Doral","sequence":"additional","affiliation":[{"name":"6Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-6166","authenticated-orcid":false,"given":"Stacy E.","family":"Croteau","sequence":"additional","affiliation":[{"name":"8Boston Hemophilia Center, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lambert","sequence":"additional","affiliation":[{"name":"9Haemophilia Care Centre, Bic\u00eatre AP-HP Hospital, Facult\u00e9 de M\u00e9decine Paris XI, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-2016","authenticated-orcid":false,"given":"Christine L.","family":"Kempton","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[{"name":"11University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Ko","sequence":"additional","affiliation":[{"name":"6Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Trzaskoma","sequence":"additional","affiliation":[{"name":"6Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dhalluin","sequence":"additional","affiliation":[{"name":"7F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nives Selak","family":"Bienz","sequence":"additional","affiliation":[{"name":"7F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Niggli","sequence":"additional","affiliation":[{"name":"7F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Lehle","sequence":"additional","affiliation":[{"name":"7F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Paz-Priel","sequence":"additional","affiliation":[{"name":"6Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[{"name":"12Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-3499","authenticated-orcid":false,"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"13La Paz Hospital, Aut\u00f3noma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"issue":"2","key":"2023053018350366500_bib1","article-title":"Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery","author":"Coppola","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"898","key":"2023053018350366500_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/pmj.76.898.494","article-title":"General surgery in haemophiliac patients","volume":"76","author":"Bastounis","year":"2000","journal-title":"Postgrad Med J"},{"issue":"suppl 6","key":"2023053018350366500_bib3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2023053018350366500_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2516.2012.02894.x","article-title":"Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres","volume":"18","author":"Escobar","year":"2012","journal-title":"Haemophilia"},{"issue":"2 suppl 1","key":"2023053018350366500_bib5","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1053\/j.seminhematol.2008.03.009","article-title":"Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors","volume":"45","author":"Jim\u00e9nez-Yuste","year":"2008","journal-title":"Semin Hematol"},{"issue":"1","key":"2023053018350366500_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2012.02922.x","article-title":"Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects","volume":"19","author":"Kulkarni","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"2023053018350366500_bib7","first-page":"478","article-title":"The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors","volume":"15","author":"Castaman","year":"2017","journal-title":"Blood Transfus"},{"issue":"2","key":"2023053018350366500_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12028","article-title":"Consensus recommendations for the use of FEIBA(\u00ae) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery","volume":"19","author":"Rangarajan","year":"2013","journal-title":"Haemophilia"},{"issue":"7","key":"2023053018350366500_bib9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023053018350366500_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cpdd.617","article-title":"Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers","volume":"8","author":"Kotani","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"2023053018350366500_bib11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2023053018350366500_bib12","unstructured":"Genentech Inc\n          . HEMLIBRA\u00ae (emicizumab-kxwh) injection for subcutaneous use, prescribing information. [Initital U.S. approval: 2017]. Available at:. Accessed 22 August 2022. https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf."},{"key":"2023053018350366500_bib13","unstructured":"F. Hoffmann-La Roche Ltd\n          . Hemlibra\u00ae summary of product characteristics. Available at:. Accessed 22 August 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf."},{"issue":"9","key":"2023053018350366500_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023053018350366500_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2023053018350366500_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023053018350366500_bib17","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"16","key":"2023053018350366500_bib18","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023053018350366500_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.13817","article-title":"Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra\u00ae): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)","volume":"25","author":"Susen","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"2023053018350366500_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","article-title":"Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms","volume":"13","author":"Lillicrap","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2023053018350366500_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hae.14322","article-title":"Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"2023053018350366500_bib22","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/hae.14010","article-title":"Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel","volume":"27","author":"Escuriola-Ettingshausen","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2023053018350366500_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hae.12518","article-title":"Safety and efficacy of turoctocog alfa (NovoEight\u00ae) during surgery in patients with haemophilia A: results from the multinational guardian\u2122 clinical trials","volume":"21","author":"Santagostino","year":"2015","journal-title":"Haemophilia"},{"issue":"8","key":"2023053018350366500_bib24","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.3324\/haematol.2018.215129","article-title":"Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement","volume":"104","author":"Santagostino","year":"2019","journal-title":"Haematologica"},{"key":"2023053018350366500_bib25","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12782","article-title":"Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1\u20133","author":"Callaghan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2023053018350366500_bib26","doi-asserted-by":"crossref","first-page":"2040620719860025","DOI":"10.1177\/2040620719860025","article-title":"Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays","volume":"10","author":"Kizilocak","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"2023053018350366500_bib27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/bloodadvances.2019000228","article-title":"Emicizumab use in major orthopedic surgery","volume":"3","author":"Seaman","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2023053018350366500_bib28","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1055\/s-0039-3401001","article-title":"Successful perioperative combination of high-dose FVIII therapy followed by emicizumab in a patient with hemophilia A with inhibitors","volume":"3","author":"Okamoto","year":"2019","journal-title":"TH Open"},{"issue":"1","key":"2023053018350366500_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2023053018350366500_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2023053018350366500_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-134906","article-title":"A\u00a0Phase IV, multicenter, open-label study of emicizumab prophylaxis in persons with hemophilia A with or without FVIII inhibitors undergoing minor surgical procedures","volume":"136","author":"Escobar","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023053018350366500_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"issue":"11","key":"2023053018350366500_bib33","doi-asserted-by":"crossref","first-page":"e29325","DOI":"10.1002\/pbc.29325","article-title":"Emicizumab in pediatric hemophilia: bleeding and surgical outcomes from a single-center retrospective study","volume":"68","author":"Cohen","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2023053018350366500_bib34","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1111\/hae.14358","article-title":"Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: experience from a large haemophilia centre in the UK","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2023053018350366500_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/hae.14459","article-title":"Port removal in patients receiving emicizumab prophylaxis: a single centre experience and review of the literature","volume":"28","author":"Swan","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"2023053018350366500_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"Ebbert","year":"2020","journal-title":"Haemophilia"},{"issue":"7","key":"2023053018350366500_bib37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"2023053018350366500_bib38","unstructured":"National Hemophilia Association\n          . MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors. MASAC Document #258. Available at:. Accessed 22 August 2022. https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/258_emicizumab.pdf."},{"issue":"11","key":"2023053018350366500_bib39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6140\/2054493\/blooda_adv-2022-007458-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6140\/2054493\/blooda_adv-2022-007458-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:37:16Z","timestamp":1685471836000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/24\/6140\/486138\/Surgical-outcomes-in-people-with-hemophilia-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007458","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}